Search Results - "Pearlberg, Joseph"

Rapid “Open-Source” Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification by Maeder, Morgan L., Thibodeau-Beganny, Stacey, Osiak, Anna, Wright, David A., Anthony, Reshma M., Eichtinger, Magdalena, Jiang, Tao, Foley, Jonathan E., Winfrey, Ronnie J., Townsend, Jeffrey A., Unger-Wallace, Erica, Sander, Jeffry D., Müller-Lerch, Felix, Fu, Fengli, Pearlberg, Joseph, Göbel, Carl, Dassie, Justin P., Pruett-Miller, Shondra M., Porteus, Matthew H., Sgroi, Dennis C., Iafrate, A. John, Dobbs, Drena, McCray, Paul B., Cathomen, Toni, Voytas, Daniel F., Joung, J. Keith

“…Custom-made zinc-finger nucleases (ZFNs) can induce targeted genome modifications with high efficiency in cell types including Drosophila, C. elegans, plants,…”
Get full text

ErbB-3 Mediates Phosphoinositide 3-Kinase Activity in Gefitinib-Sensitive Non-Small Cell Lung Cancer Cell Lines by Engelman, Jeffrey A., Jänne, Pasi A., Mermel, Craig, Pearlberg, Joseph, Mukohara, Toru, Fleet, Christina, Cichowski, Karen, Johnson, Bruce E., Cantley, Lewis C.

“…Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a subset of patients with advanced non-small cell lung cancer…”
Get full text

High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy by Gonzalez-Malerva, Laura, Park, Jaehong, Zou, Lihua, Hu, Yanhui, Moradpour, Zahra, Pearlberg, Joseph, Sawyer, Jacqueline, Stevens, Hallam, Harlow, Ed, LaBaer, Joshua

“…Resistance to tamoxifen in breast cancer patients is a serious therapeutic problem and major efforts are underway to understand underlying mechanisms…”
Get full text

Let's get americans back to work again by Chandra, Amitabh, Jackson, Robert, Karnal, Alexander, Pearlberg, Joseph

Get full text

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations by Mukohara, Toru, Engelman, Jeffrey A., Hanna, Nasser H., Yeap, Beow Y., Kobayashi, Susumu, Lindeman, Neal, Halmos, Balázs, Pearlberg, Joseph, Tsuchihashi, Zenta, Cantley, Lewis C., Tenen, Daniel G., Johnson, Bruce E., Jänne, Pasi A.

“…Background: Many patients with non–small-cell lung cancer (NSCLC) who achieve radiographic responses to treatment with the epidermal growth factor receptor…”
Get full text

Kinase requirements in human cells: I. Comparing kinase requirements across various cell types by Grueneberg, Dorre A, Degot, Sebastien, Pearlberg, Joseph, Li, Wenliang, Davies, Joan E, Baldwin, Amy, Endege, Wilson, Doench, John, Sawyer, Jacqueline, Hu, Yanhui, Boyce, Frederick, Xian, Jun, Munger, Karl, Harlow, Ed

“…shRNA loss-of-function screens were used to identify kinases that were rate-limiting for promoting cell proliferation and survival. Here, we study the…”
Get full text

Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells by Baldwin, Amy, Li, Wenliang, Grace, Miranda, Pearlberg, Joseph, Harlow, Ed, Münger, Karl, Grueneberg, Dorre A

“…Human papillomavirus (HPV) oncoproteins subvert cellular signaling pathways, including kinase pathways, during the carcinogenic process. To identify kinases…”
Get full text

Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines by Grueneberg, Dorre A, Li, Wenliang, Davies, Joan E, Sawyer, Jacqueline, Pearlberg, Joseph, Harlow, Ed

“…Functional differences among human cells have been difficult to identify by standard biochemical methods. Loss-of-function shRNA screens provide an unbiased…”
Get full text

A biomedically enriched collection of 7000 human ORF clones by Rolfs, Andreas, Hu, Yanhui, Ebert, Lars, Hoffmann, Dietmar, Zuo, Dongmei, Ramachandran, Niro, Raphael, Jacob, Kelley, Fontina, McCarron, Seamus, Jepson, Daniel A, Shen, Binghua, Baqui, Munira M A, Pearlberg, Joseph, Taycher, Elena, DeLoughery, Craig, Hoerlein, Andreas, Korn, Bernhard, LaBaer, Joshua

“…We report the production and availability of over 7000 fully sequence verified plasmid ORF clones representing over 3400 unique human genes. These ORF clones…”
Get full text

Deleterious Effects of Hepatitis Delta Virus Replication on Host Cell Proliferation by Wang, D, Pearlberg, J, Liu, Y T, Ganem, D

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer by Liu, Joyce F, Ray-Coquard, Isabelle, Selle, Frederic, Poveda, Andrés M, Cibula, David, Hirte, Hal, Hilpert, Felix, Raspagliesi, Francesco, Gladieff, Laurence, Harter, Philipp, Siena, Salvatore, Del Campo, Josep Maria, Tabah-Fisch, Isabelle, Pearlberg, Joseph, Moyo, Victor, Riahi, Kaveh, Nering, Rachel, Kubasek, William, Adiwijaya, Bambang, Czibere, Akos, Naumann, R Wendel, Coleman, Robert L, Vergote, Ignace, MacBeath, Gavin, Pujade-Lauraine, Eric

“…Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking…”
Get full text

Targeted mutagenesis in zebrafish using customized zinc-finger nucleases by Yeh, Jing-Ruey J, Foley, Jonathan E, Maeder, Morgan L, Pearlberg, Joseph, Joung, J Keith, Peterson, Randall T

“…Zebrafish mutants have traditionally been obtained by using random mutagenesis or retroviral insertions, methods that cannot be targeted to a specific gene and…”
Get full text

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors by Abramson, Vandana G, Supko, Jeffrey G, Ballinger, Tarah, Cleary, James M, Hilton, John F, Tolaney, Sara M, Chau, Nicole G, Cho, Daniel C, Pearlberg, Joseph, Lager, Joanne, Shapiro, Geoffrey I, Arteaga, Carlos L

“…This phase Ib study was designed to determine the MTD, safety, preliminary efficacy, and pharmacokinetics of the HER3 (ErbB3) mAb SAR256212 in combination with…”
Get full text

FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen by Fowler, Nathan Hale, Pearlberg, Joseph, Brail, Les H., Shi, Weiliang, Jiang, Liewen, Condon, Carrie, Rummel, Mathias J.

“…Abstract only…”
Get full text

Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma by Casulo, Carla, Jacobsen, Eric D., Van Eygen, Koen, Holmes, Houston Eccleston, Lemmens, Jan P., Allen, Kerstin, Steelman, Lori, Campbell, Veronica, Nevejans, Jylle, Pearlberg, Joseph, Goy, Andre

“…Abstract only…”
Get full text

Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors by Tolcher, Anthony, Hong, David, Sullivan, Ryan, Mier, James, Shapiro, Geoffrey, Chmielowski, Bartosz, Ribas, Antoni, Postow, Michael, Pearlberg, Joseph, Brail, Les, Lee, Lucy, Ullmann, Claudio A. Dansky, Wolchok, Jedd D.

“…Abstract Background: IPI-549 is a potentially first-in-class, oral, potent, and selective inhibitor of PI3K-γ that shows single agent antitumor activity in…”
Get full text

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab by Casulo, Carla, Sancho, Juan-Manuel, Van Eygen, Koen, de Vos, Sven, Mercadal, Santiago, Johnson, Roderick J., Bouabdallah, Kamal, Holmes, Houston, Lemmens, Jan, Gyan, Emmanuel, Merli, Michele, Advani, Ranjana H, Steelman, Lori, Pearlberg, Joseph, Goy, Andre

“…Background: Duvelisib is an oral, dual inhibitor of PI3K-d,γ, in development for the treatment of hematologic malignancies, including follicular lymphoma (FL)…”
Get full text

IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors by Tolcher, Anthony W., Hong, David S., Sullivan, Ryan J., Mier, James Walter, Shapiro, Geoffrey, Pearlberg, Joseph, Brail, Les H., Kharidia, Jahnavi, Han, Lixin, Dansky Ullmann, Claudio, Stern, Howard Marvin, Wolchok, Jedd D.

“…Abstract only…”
Get full text

A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers by Cleary, James M., McRee, Autumn Jackson, O'Neil, Bert H., Sharma, Sunil, Pearlberg, Joseph, Manoli, Sara, Kubasek, William Lloyd, Korn, W. Michael

“…Abstract only…”
Get full text

A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer by Higgins, Michaela Jane, Doyle, Catherine, Paepke, Stefan, Azaro, Analia, Martin, Miguel, Semiglazov, Vladimir, Smirnova, Iya, Krasnozhon, Dmitriy, Manikhas, Alexey, Harb, Wael A., Panasci, Lawrence C., Pearlberg, Joseph, MacBeath, Gavin, Nering, Rachel, Goss, Paul E., Miller, Kathy

“…Abstract only…”
Get full text